China biotech licensing deals are reshaping 2028 formularies

What the October 2026 deal wave actually bought

Roche entered the emerging ALK7 obesity race through a deal worth up to $1.2 billion with China's Rona Therapeutics, according to Fierce Biotech reporting from the week of Oct. 13. In the same window, AstraZeneca committed $2 billion to Summit Therapeutics to push the PD-1xVEGF bispecific ivonescimab into antibody-drug conjugate combinations. Ivonescimab itself originated with China's Akeso, making the AstraZeneca commitment a second-order bet on a China-discovered molecule.

Clinical readouts moved in the same direction. Biokin and Bristol Myers Squibb reported that their bispecific ADC iza-bren met its primary endpoint in an EGFR-mutated non-small cell lung cancer trial conducted in China, a result Fierce Pharma framed as a direct competitive threat to TROP2-targeted ADCs already in US use. Meanwhile, Fierce Biotech's fundraising tracker shows US startups now being founded around in-licensed Chinese assets outright, including a Boston company built on porustobart, a CTLA-4 antibody licensed from Harbour BioMed.

Pfizer's $500 million Enodia pact in protein degraders rounds out the picture. The modality differs, but the posture is identical: license first, scale later. For formulary planners, the signal is that the license-first model has moved from an opportunistic tactic to a default sourcing strategy across obesity, oncology and emerging small-molecule classes.

The drugs reaching P&T review in 2028 will arrive with trial dossiers, ownership structures and supply chains that look different from what most committees are used to evaluating.

Headline value is not cash, and forecasting models should reflect that

The deal values dominating headlines are biodollar totals, not committed capital. Zealand's up-to-$1.2 billion obesity pact with Generate Biomedicines carries only $30 million upfront, a ratio that is typical rather than exceptional. Treating headline figures as a proxy for program conviction will distort any forecast built on them.

The practical consequence for budget-impact modeling is that deal announcements are weak predictors of launch timing. A $2 billion commitment with real near-term capital behind it, as in AstraZeneca and Summit, implies a different development pace than a $1.2 billion structure where most value sits behind distant regulatory and sales milestones. Pharmacy and finance teams reviewing pipeline intelligence should ask vendors to report upfront payments and near-term committed spend alongside headline totals.

Single-country pivotal data meets a tougher FDA

The same two weeks delivered a counterweight. BioNTech's mRNA cancer vaccine failed a phase 3 test on Oct. 13, 2026, a reminder that well-capitalized programs still break. More consequential for review committees, Fierce Pharma's regulatory tracker reported the FDA again rebuffing Pierre Fabre's Ebvallo, this time over single-arm trial design that the agency had previously found acceptable. It was the third attempt.

That combination defines the risk profile ahead. Evidence standards are tightening at the agency precisely as pivotal efficacy data increasingly originates from largely single-country trials. Submissions arriving in 2027 and 2028 may pair strong effect sizes from Chinese patient populations with questions about generalizability, comparator choice and bridging studies. Committees that currently treat geography as a footnote in evidence appraisal will need an explicit position on it.

None of this makes China-origin assets weaker. Iza-bren's readout was a clean primary endpoint hit. The point is that approval probability and the evidence package a committee eventually reviews are now less correlated with sponsor size and brand familiarity than they were five years ago.

Faster class entry compresses contracting windows

Historic launch curves assume a gap of several years between a first-in-class product and credible second or third entrants. The license-first model shortens that gap. When multiple large sponsors can acquire late-preclinical or early-clinical assets in the same mechanism within months of one another, as is now happening in ALK7 obesity and PD-1xVEGF oncology, class-level competition arrives earlier than most multi-year contracts anticipate.

For payers and health system pharmacy leaders, that argues for shorter contract terms or explicit renegotiation triggers in obesity and oncology categories specifically. A three-year exclusivity arrangement signed in 2026 on the assumption of a single dominant agent could leave an organization locked out of price competition that materializes in 2028. Net-price dynamics in crowded classes historically move faster than list prices, so rebate structures deserve the same scrutiny as formulary placement.

Diligence questions worth adding now

Supply continuity is the least discussed exposure. When the US commercial owner is not the originator, manufacturing, fill-finish and active ingredient sourcing may sit with partners that a health system has never assessed. Vendor diligence frameworks built around a single integrated manufacturer do not capture that structure well.

Three additions are low effort and high value. First, require pipeline intelligence that flags asset origin and the identity of the commercial owner, not just the marketing sponsor. Second, add a question on manufacturing geography and dual-sourcing to new product onboarding. Third, build a watchlist of mechanisms where two or more sponsors are developing in parallel, and align contract renewal dates against expected second-entrant timing rather than against the calendar.